Celltrion to Unveil Drug Development Plans at JP Morgan Conference
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
179,600.00 KRW | -0.77% |
|
-0.06% | -4.21% |
Feb. 04 | South Korean Shares Rally on US Tariff Delay; Celltrion Shares Rise 1% on FDA Approval for ACTEMRA Biosimilar | MT |
Feb. 03 | Celltrion Secures FDA Approval for AVTOZMA Tocilizumab Biosimilar | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration